Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12183066 | 0.93 | PDPK1 (0.43) | PDPK1MAP2K1MTORATMSLC6A4 | |
| SCHEMBL12182780 | 0.83 | PDPK1 (0.42) | PDPK1MAP2K1MTORPDE4APDE4B | |
| SCHEMBL9602829 | 0.81 | PDPK1 (0.44) | PDPK1MTORHTR6PDE4APDE4B | |
| SCHEMBL12183222 | 0.81 | PDPK1 (0.41) | PDPK1MAP2K1PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL9603162 | 0.79 | PDPK1 (0.43) | PDPK1MTORHTR6PDE4APDE4B | |
| SCHEMBL12183127 | 0.78 | MTOR (0.42) | PDPK1MTORATM | |
| SCHEMBL12182749 | 0.71 | PDPK1 (0.37) | PDPK1ATMPARP1 | |
| SCHEMBL6838085 | 0.69 | TLR7 (0.51) | — | |
| SCHEMBL24381749 | 0.69 | ATM (0.57) | MTORATM | |
| SCHEMBL12182782 | 0.68 | JAK1 (0.45) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | PDPK1 2768/4885MAP2K1 4408/4885MTOR 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.